nodes	percent_of_prediction	percent_of_DWPC	metapath
Lapatinib—TAP1—adrenal cortex—polycystic ovary syndrome	0.0116	0.0346	CbGeAlD
Lapatinib—PIK3C2B—adrenal cortex—polycystic ovary syndrome	0.0109	0.0325	CbGeAlD
Lapatinib—TAP1—endometrium—polycystic ovary syndrome	0.0104	0.0309	CbGeAlD
Lapatinib—ERBB4—embryo—polycystic ovary syndrome	0.0104	0.0308	CbGeAlD
Lapatinib—ERBB2—embryo—polycystic ovary syndrome	0.0104	0.0308	CbGeAlD
Lapatinib—CYP2C19—urine—polycystic ovary syndrome	0.00999	0.0297	CbGeAlD
Lapatinib—PIK3C2B—endometrium—polycystic ovary syndrome	0.00976	0.029	CbGeAlD
Lapatinib—TAP1—pituitary gland—polycystic ovary syndrome	0.00941	0.028	CbGeAlD
Lapatinib—TAP1—adipose tissue—polycystic ovary syndrome	0.00937	0.0278	CbGeAlD
Lapatinib—PIK3C2B—pituitary gland—polycystic ovary syndrome	0.00883	0.0263	CbGeAlD
Lapatinib—PIK3C2B—adipose tissue—polycystic ovary syndrome	0.0088	0.0261	CbGeAlD
Lapatinib—Nail disorder—Metformin—polycystic ovary syndrome	0.00854	0.0916	CcSEcCtD
Lapatinib—TAP1—adrenal gland—polycystic ovary syndrome	0.00841	0.025	CbGeAlD
Lapatinib—PI4KB—adrenal cortex—polycystic ovary syndrome	0.00796	0.0237	CbGeAlD
Lapatinib—PIK3C2B—adrenal gland—polycystic ovary syndrome	0.00789	0.0235	CbGeAlD
Lapatinib—TAP1—female gonad—polycystic ovary syndrome	0.00784	0.0233	CbGeAlD
Lapatinib—TAP1—vagina—polycystic ovary syndrome	0.00779	0.0232	CbGeAlD
Lapatinib—ERBB2—endometrium—polycystic ovary syndrome	0.00759	0.0226	CbGeAlD
Lapatinib—PIK3C2B—female gonad—polycystic ovary syndrome	0.00736	0.0219	CbGeAlD
Lapatinib—PIK3C2B—vagina—polycystic ovary syndrome	0.00731	0.0217	CbGeAlD
Lapatinib—PI4KB—endometrium—polycystic ovary syndrome	0.00711	0.0211	CbGeAlD
Lapatinib—ERBB2—uterus—polycystic ovary syndrome	0.007	0.0208	CbGeAlD
Lapatinib—ERBB4—pituitary gland—polycystic ovary syndrome	0.00687	0.0204	CbGeAlD
Lapatinib—PIK3C2B—endocrine gland—polycystic ovary syndrome	0.00684	0.0203	CbGeAlD
Lapatinib—ERBB2—adipose tissue—polycystic ovary syndrome	0.00684	0.0203	CbGeAlD
Lapatinib—ERBB4—adipose tissue—polycystic ovary syndrome	0.00684	0.0203	CbGeAlD
Lapatinib—Blood disorder—Metformin—polycystic ovary syndrome	0.00664	0.0711	CcSEcCtD
Lapatinib—PI4KB—uterus—polycystic ovary syndrome	0.00655	0.0195	CbGeAlD
Lapatinib—PI4KB—pituitary gland—polycystic ovary syndrome	0.00643	0.0191	CbGeAlD
Lapatinib—PI4KB—adipose tissue—polycystic ovary syndrome	0.00641	0.019	CbGeAlD
Lapatinib—ERBB2—adrenal gland—polycystic ovary syndrome	0.00614	0.0182	CbGeAlD
Lapatinib—EGFR—uterus—polycystic ovary syndrome	0.00593	0.0176	CbGeAlD
Lapatinib—CYP3A4—urine—polycystic ovary syndrome	0.00591	0.0176	CbGeAlD
Lapatinib—EGFR—adipose tissue—polycystic ovary syndrome	0.0058	0.0172	CbGeAlD
Lapatinib—PI4KB—adrenal gland—polycystic ovary syndrome	0.00575	0.0171	CbGeAlD
Lapatinib—ERBB2—female gonad—polycystic ovary syndrome	0.00572	0.017	CbGeAlD
Lapatinib—ERBB4—vagina—polycystic ovary syndrome	0.00569	0.0169	CbGeAlD
Lapatinib—PI4KB—female gonad—polycystic ovary syndrome	0.00536	0.0159	CbGeAlD
Lapatinib—PI4KB—vagina—polycystic ovary syndrome	0.00533	0.0158	CbGeAlD
Lapatinib—ERBB2—endocrine gland—polycystic ovary syndrome	0.00532	0.0158	CbGeAlD
Lapatinib—ERBB4—endocrine gland—polycystic ovary syndrome	0.00532	0.0158	CbGeAlD
Lapatinib—EGFR—adrenal gland—polycystic ovary syndrome	0.0052	0.0155	CbGeAlD
Lapatinib—PI4KB—endocrine gland—polycystic ovary syndrome	0.00498	0.0148	CbGeAlD
Lapatinib—EGFR—female gonad—polycystic ovary syndrome	0.00485	0.0144	CbGeAlD
Lapatinib—Pain in extremity—Metformin—polycystic ovary syndrome	0.00402	0.0431	CcSEcCtD
Lapatinib—Dehydration—Metformin—polycystic ovary syndrome	0.00374	0.0401	CcSEcCtD
Lapatinib—Neutropenia—Metformin—polycystic ovary syndrome	0.00325	0.0349	CcSEcCtD
Lapatinib—Infestation NOS—Metformin—polycystic ovary syndrome	0.0031	0.0332	CcSEcCtD
Lapatinib—Infestation—Metformin—polycystic ovary syndrome	0.0031	0.0332	CcSEcCtD
Lapatinib—Neuropathy peripheral—Metformin—polycystic ovary syndrome	0.00304	0.0326	CcSEcCtD
Lapatinib—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.00293	0.0314	CcSEcCtD
Lapatinib—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.00273	0.0293	CcSEcCtD
Lapatinib—Cardiac disorder—Metformin—polycystic ovary syndrome	0.00258	0.0277	CcSEcCtD
Lapatinib—Angiopathy—Metformin—polycystic ovary syndrome	0.00253	0.0271	CcSEcCtD
Lapatinib—Immune system disorder—Metformin—polycystic ovary syndrome	0.00251	0.027	CcSEcCtD
Lapatinib—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.00251	0.0269	CcSEcCtD
Lapatinib—Malnutrition—Metformin—polycystic ovary syndrome	0.00242	0.026	CcSEcCtD
Lapatinib—Palpitations—Metformin—polycystic ovary syndrome	0.00214	0.023	CcSEcCtD
Lapatinib—CYP2C8—endometrium—polycystic ovary syndrome	0.00206	0.00613	CbGeAlD
Lapatinib—Myalgia—Metformin—polycystic ovary syndrome	0.00206	0.0221	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.00205	0.022	CcSEcCtD
Lapatinib—Infection—Metformin—polycystic ovary syndrome	0.00196	0.0211	CcSEcCtD
Lapatinib—Nervous system disorder—Metformin—polycystic ovary syndrome	0.00194	0.0208	CcSEcCtD
Lapatinib—Skin disorder—Metformin—polycystic ovary syndrome	0.00192	0.0206	CcSEcCtD
Lapatinib—Anorexia—Metformin—polycystic ovary syndrome	0.00188	0.0202	CcSEcCtD
Lapatinib—CYP2C8—pituitary gland—polycystic ovary syndrome	0.00187	0.00555	CbGeAlD
Lapatinib—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.0018	0.0193	CcSEcCtD
Lapatinib—CYP2C19—vagina—polycystic ovary syndrome	0.00177	0.00526	CbGeAlD
Lapatinib—Dyspnoea—Metformin—polycystic ovary syndrome	0.00176	0.0189	CcSEcCtD
Lapatinib—Dyspepsia—Metformin—polycystic ovary syndrome	0.00174	0.0187	CcSEcCtD
Lapatinib—Decreased appetite—Metformin—polycystic ovary syndrome	0.00172	0.0184	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.00171	0.0183	CcSEcCtD
Lapatinib—Fatigue—Metformin—polycystic ovary syndrome	0.0017	0.0183	CcSEcCtD
Lapatinib—Constipation—Metformin—polycystic ovary syndrome	0.00169	0.0181	CcSEcCtD
Lapatinib—CYP3A5—adipose tissue—polycystic ovary syndrome	0.00168	0.00499	CbGeAlD
Lapatinib—CYP2C19—endocrine gland—polycystic ovary syndrome	0.00166	0.00492	CbGeAlD
Lapatinib—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.00162	0.0173	CcSEcCtD
Lapatinib—Abdominal pain—Metformin—polycystic ovary syndrome	0.00156	0.0168	CcSEcCtD
Lapatinib—CYP2C8—vagina—polycystic ovary syndrome	0.00155	0.00459	CbGeAlD
Lapatinib—CYP2C8—endocrine gland—polycystic ovary syndrome	0.00145	0.0043	CbGeAlD
Lapatinib—Asthenia—Metformin—polycystic ovary syndrome	0.00142	0.0152	CcSEcCtD
Lapatinib—CYP3A5—female gonad—polycystic ovary syndrome	0.0014	0.00417	CbGeAlD
Lapatinib—Pruritus—Metformin—polycystic ovary syndrome	0.0014	0.015	CcSEcCtD
Lapatinib—CYP3A5—vagina—polycystic ovary syndrome	0.0014	0.00415	CbGeAlD
Lapatinib—Diarrhoea—Metformin—polycystic ovary syndrome	0.00135	0.0145	CcSEcCtD
Lapatinib—ABCB1—embryo—polycystic ovary syndrome	0.00135	0.00402	CbGeAlD
Lapatinib—CYP3A5—endocrine gland—polycystic ovary syndrome	0.00131	0.00388	CbGeAlD
Lapatinib—Vomiting—Metformin—polycystic ovary syndrome	0.00126	0.0135	CcSEcCtD
Lapatinib—Rash—Metformin—polycystic ovary syndrome	0.00125	0.0134	CcSEcCtD
Lapatinib—Dermatitis—Metformin—polycystic ovary syndrome	0.00125	0.0134	CcSEcCtD
Lapatinib—Headache—Metformin—polycystic ovary syndrome	0.00124	0.0133	CcSEcCtD
Lapatinib—Nausea—Metformin—polycystic ovary syndrome	0.00117	0.0126	CcSEcCtD
Lapatinib—ABCB1—adrenal cortex—polycystic ovary syndrome	0.00111	0.00329	CbGeAlD
Lapatinib—ABCB1—endometrium—polycystic ovary syndrome	0.000989	0.00294	CbGeAlD
Lapatinib—CYP3A4—endocrine gland—polycystic ovary syndrome	0.00098	0.00291	CbGeAlD
Lapatinib—Gefitinib—CYP1A1—polycystic ovary syndrome	0.000936	1	CrCbGaD
Lapatinib—ABCB1—uterus—polycystic ovary syndrome	0.000911	0.00271	CbGeAlD
Lapatinib—ABCB1—pituitary gland—polycystic ovary syndrome	0.000895	0.00266	CbGeAlD
Lapatinib—ABCB1—adipose tissue—polycystic ovary syndrome	0.000891	0.00265	CbGeAlD
Lapatinib—ABCB1—adrenal gland—polycystic ovary syndrome	0.0008	0.00238	CbGeAlD
Lapatinib—ABCB1—female gonad—polycystic ovary syndrome	0.000746	0.00222	CbGeAlD
Lapatinib—ABCB1—vagina—polycystic ovary syndrome	0.000741	0.0022	CbGeAlD
Lapatinib—ABCB1—endocrine gland—polycystic ovary syndrome	0.000693	0.00206	CbGeAlD
Lapatinib—EGFR—Immune System—ATF1—polycystic ovary syndrome	5.07e-05	8.9e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—AKT2—polycystic ovary syndrome	5.04e-05	8.85e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—NRG1—polycystic ovary syndrome	5.02e-05	8.82e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—AKT2—polycystic ovary syndrome	4.96e-05	8.72e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—AKR1C1—polycystic ovary syndrome	4.92e-05	8.65e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—IRS1—polycystic ovary syndrome	4.89e-05	8.59e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—SCT—polycystic ovary syndrome	4.87e-05	8.56e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—SRD5A1—polycystic ovary syndrome	4.87e-05	8.55e-05	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—polycystic ovary syndrome	4.84e-05	8.49e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—ADRB2—polycystic ovary syndrome	4.81e-05	8.45e-05	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—IL6—polycystic ovary syndrome	4.79e-05	8.42e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—SERPINE1—polycystic ovary syndrome	4.79e-05	8.41e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—HMMR—polycystic ovary syndrome	4.78e-05	8.4e-05	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—BCL2—polycystic ovary syndrome	4.77e-05	8.37e-05	CbGpPWpGaD
Lapatinib—ABCB1—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	4.76e-05	8.36e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—SERPINE1—polycystic ovary syndrome	4.72e-05	8.28e-05	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—IRS1—polycystic ovary syndrome	4.7e-05	8.25e-05	CbGpPWpGaD
Lapatinib—EGFR—Axon guidance—VEGFA—polycystic ovary syndrome	4.7e-05	8.25e-05	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—BCL2—polycystic ovary syndrome	4.69e-05	8.25e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—TAB1—polycystic ovary syndrome	4.67e-05	8.21e-05	CbGpPWpGaD
Lapatinib—EGFR—NGF signalling via TRKA from the plasma membrane—IL6—polycystic ovary syndrome	4.67e-05	8.2e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MTNR1B—polycystic ovary syndrome	4.65e-05	8.16e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—STAR—polycystic ovary syndrome	4.65e-05	8.16e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—PRL—polycystic ovary syndrome	4.63e-05	8.14e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	4.59e-05	8.07e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PNPLA2—polycystic ovary syndrome	4.59e-05	8.05e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—FGF18—polycystic ovary syndrome	4.57e-05	8.02e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—HSD3B1—polycystic ovary syndrome	4.56e-05	8.01e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—TCF7L2—polycystic ovary syndrome	4.56e-05	8.01e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—NMNAT3—polycystic ovary syndrome	4.55e-05	7.99e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—RBP4—polycystic ovary syndrome	4.53e-05	7.96e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—AKT2—polycystic ovary syndrome	4.53e-05	7.95e-05	CbGpPWpGaD
Lapatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	4.51e-05	7.92e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—SLC2A4—polycystic ovary syndrome	4.48e-05	7.88e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PNPLA2—polycystic ovary syndrome	4.48e-05	7.86e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—GNAS—polycystic ovary syndrome	4.46e-05	7.83e-05	CbGpPWpGaD
Lapatinib—ABCB1—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	4.42e-05	7.77e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—IRS2—polycystic ovary syndrome	4.37e-05	7.67e-05	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—AKT2—polycystic ovary syndrome	4.35e-05	7.64e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—SRD5A1—polycystic ovary syndrome	4.35e-05	7.64e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—IRS2—polycystic ovary syndrome	4.3e-05	7.55e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—PRL—polycystic ovary syndrome	4.28e-05	7.51e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—LEP—polycystic ovary syndrome	4.27e-05	7.5e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—SRD5A1—polycystic ovary syndrome	4.24e-05	7.45e-05	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—IL6—polycystic ovary syndrome	4.23e-05	7.44e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—YAP1—polycystic ovary syndrome	4.23e-05	7.43e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—LEP—polycystic ovary syndrome	4.21e-05	7.39e-05	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—IL6—polycystic ovary syndrome	4.17e-05	7.33e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—GAB1—polycystic ovary syndrome	4.17e-05	7.33e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—LPCAT2—polycystic ovary syndrome	4.16e-05	7.31e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—SUOX—polycystic ovary syndrome	4.16e-05	7.31e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—LHB—polycystic ovary syndrome	4.16e-05	7.31e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—STAR—polycystic ovary syndrome	4.15e-05	7.28e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—HMMR—polycystic ovary syndrome	4.14e-05	7.27e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	4.1e-05	7.2e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—HSD3B2—polycystic ovary syndrome	4.07e-05	7.14e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—STAR—polycystic ovary syndrome	4.05e-05	7.11e-05	CbGpPWpGaD
Lapatinib—ABCB1—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	4.05e-05	7.11e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—INSR—polycystic ovary syndrome	3.99e-05	7e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—BCL2—polycystic ovary syndrome	3.96e-05	6.95e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—HSD3B1—polycystic ovary syndrome	3.95e-05	6.94e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—AKR1C1—polycystic ovary syndrome	3.94e-05	6.92e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	3.91e-05	6.86e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IL18—polycystic ovary syndrome	3.9e-05	6.85e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ISYNA1—polycystic ovary syndrome	3.87e-05	6.8e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Biological oxidations—POMC—polycystic ovary syndrome	3.86e-05	6.78e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—IRS1—polycystic ovary syndrome	3.81e-05	6.69e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—NRG1—polycystic ovary syndrome	3.81e-05	6.69e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—AKR1C3—polycystic ovary syndrome	3.79e-05	6.66e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—IRS1—polycystic ovary syndrome	3.75e-05	6.59e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TNRC6B—polycystic ovary syndrome	3.73e-05	6.55e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	3.7e-05	6.5e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—HMMR—polycystic ovary syndrome	3.7e-05	6.49e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PGR—polycystic ovary syndrome	3.69e-05	6.49e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—POMC—polycystic ovary syndrome	3.67e-05	6.45e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—INS—polycystic ovary syndrome	3.65e-05	6.41e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—SULT2A1—polycystic ovary syndrome	3.62e-05	6.36e-05	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—polycystic ovary syndrome	3.62e-05	6.36e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—POMC—polycystic ovary syndrome	3.61e-05	6.35e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—HMMR—polycystic ovary syndrome	3.61e-05	6.34e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—LHB—polycystic ovary syndrome	3.6e-05	6.33e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—INS—polycystic ovary syndrome	3.59e-05	6.31e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—IL6—polycystic ovary syndrome	3.59e-05	6.3e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—NCOR1—polycystic ovary syndrome	3.58e-05	6.3e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—IGF1—polycystic ovary syndrome	3.53e-05	6.2e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—AKT2—polycystic ovary syndrome	3.53e-05	6.2e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—HSD3B1—polycystic ovary syndrome	3.53e-05	6.19e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—HSD3B2—polycystic ovary syndrome	3.52e-05	6.19e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—NRG1—polycystic ovary syndrome	3.52e-05	6.18e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—RRM2—polycystic ovary syndrome	3.51e-05	6.16e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	3.49e-05	6.12e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—IGF1—polycystic ovary syndrome	3.48e-05	6.11e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—AKT2—polycystic ovary syndrome	3.47e-05	6.1e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—HSD3B1—polycystic ovary syndrome	3.44e-05	6.05e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PLAT—polycystic ovary syndrome	3.43e-05	6.03e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—GHRL—polycystic ovary syndrome	3.43e-05	6.03e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—AKR1C1—polycystic ovary syndrome	3.41e-05	5.99e-05	CbGpPWpGaD
Lapatinib—ABCB1—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	3.4e-05	5.96e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—YAP1—polycystic ovary syndrome	3.38e-05	5.94e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.35e-05	5.89e-05	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—VEGFA—polycystic ovary syndrome	3.35e-05	5.89e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	3.3e-05	5.8e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.3e-05	5.8e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—TEAD2—polycystic ovary syndrome	3.29e-05	5.78e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—AKR1C2—polycystic ovary syndrome	3.29e-05	5.78e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—ATF1—polycystic ovary syndrome	3.27e-05	5.75e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IRS2—polycystic ovary syndrome	3.26e-05	5.73e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CRP—polycystic ovary syndrome	3.26e-05	5.73e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—NAMPT—polycystic ovary syndrome	3.25e-05	5.71e-05	CbGpPWpGaD
Lapatinib—EGFR—Axon guidance—IL6—polycystic ovary syndrome	3.25e-05	5.71e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—LHB—polycystic ovary syndrome	3.22e-05	5.65e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—CYP11A1—polycystic ovary syndrome	3.21e-05	5.64e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TCF7L2—polycystic ovary syndrome	3.19e-05	5.61e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—MTHFR—polycystic ovary syndrome	3.17e-05	5.56e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—HSD3B2—polycystic ovary syndrome	3.14e-05	5.52e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—LHB—polycystic ovary syndrome	3.14e-05	5.51e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—SULT2A1—polycystic ovary syndrome	3.14e-05	5.51e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—HSD3B2—polycystic ovary syndrome	3.07e-05	5.39e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—AKR1C1—polycystic ovary syndrome	3.04e-05	5.35e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—RRM2—polycystic ovary syndrome	3.04e-05	5.34e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—AKR1C3—polycystic ovary syndrome	3.03e-05	5.32e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NGFR—polycystic ovary syndrome	3.02e-05	5.31e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—IRS2—polycystic ovary syndrome	3.01e-05	5.29e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—POMC—polycystic ovary syndrome	3e-05	5.28e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PRL—polycystic ovary syndrome	3e-05	5.26e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—CYP17A1—polycystic ovary syndrome	2.98e-05	5.24e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—AKR1C1—polycystic ovary syndrome	2.97e-05	5.22e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—YAP1—polycystic ovary syndrome	2.93e-05	5.15e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—AKT2—polycystic ovary syndrome	2.89e-05	5.07e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IRS1—polycystic ovary syndrome	2.85e-05	5.01e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—ADRB2—polycystic ovary syndrome	2.84e-05	4.99e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—NAMPT—polycystic ovary syndrome	2.82e-05	4.94e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—SULT2A1—polycystic ovary syndrome	2.8e-05	4.92e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	2.8e-05	4.92e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CYP11A1—polycystic ovary syndrome	2.78e-05	4.88e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	2.76e-05	4.85e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	2.76e-05	4.84e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—SULT2A1—polycystic ovary syndrome	2.73e-05	4.8e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—RRM2—polycystic ovary syndrome	2.71e-05	4.77e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—RRM2—polycystic ovary syndrome	2.65e-05	4.65e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—AKT2—polycystic ovary syndrome	2.64e-05	4.63e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—GNAS—polycystic ovary syndrome	2.63e-05	4.63e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—IRS1—polycystic ovary syndrome	2.63e-05	4.62e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—AKR1C3—polycystic ovary syndrome	2.63e-05	4.61e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—YAP1—polycystic ovary syndrome	2.62e-05	4.59e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	2.61e-05	4.59e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CYP17A1—polycystic ovary syndrome	2.58e-05	4.54e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—TH—polycystic ovary syndrome	2.58e-05	4.54e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—YAP1—polycystic ovary syndrome	2.55e-05	4.48e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—INS—polycystic ovary syndrome	2.52e-05	4.43e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—NAMPT—polycystic ovary syndrome	2.51e-05	4.41e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—SLC2A4—polycystic ovary syndrome	2.51e-05	4.41e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.51e-05	4.41e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	2.5e-05	4.39e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	2.49e-05	4.38e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CYP11A1—polycystic ovary syndrome	2.48e-05	4.36e-05	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—IL6—polycystic ovary syndrome	2.47e-05	4.33e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NRG1—polycystic ovary syndrome	2.46e-05	4.33e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	2.46e-05	4.33e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	2.45e-05	4.31e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—AKT2—polycystic ovary syndrome	2.44e-05	4.28e-05	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—IL6—polycystic ovary syndrome	2.43e-05	4.27e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	2.42e-05	4.25e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—CYP19A1—polycystic ovary syndrome	2.36e-05	4.15e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—AKR1C3—polycystic ovary syndrome	2.34e-05	4.12e-05	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—IL6—polycystic ovary syndrome	2.32e-05	4.07e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—SERPINE1—polycystic ovary syndrome	2.31e-05	4.06e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CYP17A1—polycystic ovary syndrome	2.31e-05	4.05e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.31e-05	4.05e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—BCL2—polycystic ovary syndrome	2.3e-05	4.05e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	2.29e-05	4.02e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—IL6—polycystic ovary syndrome	2.28e-05	4e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.27e-05	3.99e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	2.25e-05	3.95e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—IL6—polycystic ovary syndrome	2.24e-05	3.94e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—TH—polycystic ovary syndrome	2.24e-05	3.93e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	2.22e-05	3.9e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—SLC2A4—polycystic ovary syndrome	2.18e-05	3.82e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	2.12e-05	3.72e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IRS2—polycystic ovary syndrome	2.11e-05	3.71e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—GNAS—polycystic ovary syndrome	2.11e-05	3.7e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—LEP—polycystic ovary syndrome	2.07e-05	3.63e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—IL6—polycystic ovary syndrome	2.05e-05	3.6e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CYP19A1—polycystic ovary syndrome	2.05e-05	3.59e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—NCOR1—polycystic ovary syndrome	2.01e-05	3.53e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—TH—polycystic ovary syndrome	2e-05	3.51e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—TH—polycystic ovary syndrome	1.95e-05	3.42e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—SLC2A4—polycystic ovary syndrome	1.94e-05	3.41e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	1.93e-05	3.4e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—CYP1A1—polycystic ovary syndrome	1.9e-05	3.34e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	1.9e-05	3.33e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	1.89e-05	3.32e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IRS1—polycystic ovary syndrome	1.84e-05	3.24e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	1.83e-05	3.22e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CYP19A1—polycystic ovary syndrome	1.83e-05	3.21e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—GNAS—polycystic ovary syndrome	1.83e-05	3.21e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	1.78e-05	3.13e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—MTHFR—polycystic ovary syndrome	1.77e-05	3.12e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—POMC—polycystic ovary syndrome	1.77e-05	3.12e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—INS—polycystic ovary syndrome	1.76e-05	3.1e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—NCOR1—polycystic ovary syndrome	1.74e-05	3.05e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IGF1—polycystic ovary syndrome	1.71e-05	3e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—AKT2—polycystic ovary syndrome	1.71e-05	3e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	1.68e-05	2.96e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CYP1A1—polycystic ovary syndrome	1.65e-05	2.9e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	1.63e-05	2.87e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—GNAS—polycystic ovary syndrome	1.63e-05	2.86e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.62e-05	2.85e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—IL6—polycystic ovary syndrome	1.59e-05	2.8e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	1.59e-05	2.79e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	1.57e-05	2.76e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—IL6—polycystic ovary syndrome	1.57e-05	2.76e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—NCOR1—polycystic ovary syndrome	1.55e-05	2.73e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—MTHFR—polycystic ovary syndrome	1.54e-05	2.7e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	1.52e-05	2.66e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	1.51e-05	2.65e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	1.49e-05	2.62e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CYP1A1—polycystic ovary syndrome	1.47e-05	2.58e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PPARG—polycystic ovary syndrome	1.44e-05	2.53e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	1.44e-05	2.52e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—POMC—polycystic ovary syndrome	1.42e-05	2.49e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—INS—polycystic ovary syndrome	1.41e-05	2.48e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	1.41e-05	2.48e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	1.39e-05	2.44e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—MTHFR—polycystic ovary syndrome	1.37e-05	2.41e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	1.34e-05	2.35e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—IL6—polycystic ovary syndrome	1.31e-05	2.29e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PPARG—polycystic ovary syndrome	1.25e-05	2.19e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—POMC—polycystic ovary syndrome	1.23e-05	2.16e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—INS—polycystic ovary syndrome	1.22e-05	2.15e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—TH—polycystic ovary syndrome	1.2e-05	2.11e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IL6—polycystic ovary syndrome	1.19e-05	2.09e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	1.17e-05	2.05e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.11e-05	1.96e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PPARG—polycystic ovary syndrome	1.11e-05	1.95e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—IL6—polycystic ovary syndrome	1.1e-05	1.93e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	1.1e-05	1.93e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—POMC—polycystic ovary syndrome	1.1e-05	1.93e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—INS—polycystic ovary syndrome	1.09e-05	1.92e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	1.09e-05	1.91e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—POMC—polycystic ovary syndrome	1.07e-05	1.88e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—INS—polycystic ovary syndrome	1.06e-05	1.87e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	9.8e-06	1.72e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	9.33e-06	1.64e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	8.85e-06	1.55e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	8.25e-06	1.45e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IL6—polycystic ovary syndrome	7.71e-06	1.35e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	6.69e-06	1.18e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	6.6e-06	1.16e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—INS—polycystic ovary syndrome	6.56e-06	1.15e-05	CbGpPWpGaD
